Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Summary

The study investigates the effect of 4 weeks of twice daily treatment of four different doses of RPL554 (a phosphodiesterase \[PDE\]3/4 inhibitor) or placebo in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Patients will be equally allocated to one of the five treatment options.

Timeline

Start

2017-06-01

Primary completion

2018-01-23

Completion

2018-02-07

Drugs

Indications